Genelux Corporation (GNLX)
Market Cap | 58.74M |
Revenue (ttm) | 8,000 |
Net Income (ttm) | -25.78M |
Shares Out | 34.35M |
EPS (ttm) | -0.97 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 201,185 |
Open | 1.820 |
Previous Close | 1.840 |
Day's Range | 1.710 - 1.869 |
52-Week Range | 1.710 - 35.150 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 32.33 (+1,790.64%) |
Earnings Date | Aug 12, 2024 |
About GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, ... [Read more]
Financial Performance
In 2023, Genelux's revenue was $170,000, a decrease of -98.46% compared to the previous year's $11.07 million. Losses were -$28.30 million, 443.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price forecast is $32.33, which is an increase of 1,790.64% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/z/z/press15-2447050.jpg)
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten o...
![](https://cdn.snapi.dev/images/v1/y/c/press7-2446325.jpg)
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwr...
![](https://cdn.snapi.dev/images/v1/l/f/press17-2422762.jpg)
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of...
![](https://cdn.snapi.dev/images/v1/y/9/press11-2349392.jpg)
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation of Ph...
![](https://cdn.snapi.dev/images/v1/7/q/press14-2171857.jpg)
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and...
![](https://cdn.snapi.dev/images/v1/w/l/press2-2158303.jpg)
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - ...
![](https://cdn.snapi.dev/images/v1/w/s/press8-2063083.jpg)
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company'...
![](https://cdn.snapi.dev/images/v1/d/z/conf11-2054539.jpg)
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairma...
![](https://cdn.snapi.dev/images/v1/q/w/press19-2039111.jpg)
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company ...
![](https://cdn.snapi.dev/images/v1/a/s/press5-2021152.jpg)
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private pla...
![](https://cdn.snapi.dev/images/v1/d/1/press14-2002368.jpg)
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023
WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...
![](https://cdn.snapi.dev/images/v1/l/m/press9-1981527.jpg)
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as...
![](https://cdn.snapi.dev/images/v1/r/u/press12-1963757.jpg)
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in Immunolog...
![](https://cdn.snapi.dev/images/v1/g/d/press12-1952860.jpg)
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic vira...
![](https://cdn.snapi.dev/images/v1/y/c/press19-1943756.jpg)
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market...
![](https://cdn.snapi.dev/images/v1/t/i/press3-1929759.jpg)
Genelux Corporation Announces $18 Million Private Placement
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of...
![](https://cdn.snapi.dev/images/v1/g/j/press6-1908357.jpg)
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology
WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline result...
![](https://cdn.snapi.dev/images/v1/4/g/press20-1889538.jpg)
Genelux Corporation Announces $33 Million Private Placement
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of...
![](https://cdn.snapi.dev/images/v1/p/l/press11-1809306.jpg)
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pi...
![](https://cdn.snapi.dev/images/v1/i/m/image-1367899897-1717299-1724071.jpg)
Genelux IPO prices at bottom of range
Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha...
![](https://cdn.snapi.dev/images/v1/v/w/press7-1723724.jpg)
Genelux Corporation Announces Pricing of Initial Public Offering
WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation...
![](https://cdn.snapi.dev/images/v1/b/i/biotech18-1549626.jpg)
Genelux sets IPO terms, as the biotech could be valued at up to $165 millino
Genelux Corp. GNLX, has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up to $164.99 mi...